Targeting RET Receptor Tyrosine Kinase Activation in Cancer (Q37798616)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 October 2010

edit

Language	Label	Description	Also known as
English	Targeting RET Receptor Tyrosine Kinase Activation in Cancer	scientific article published on 07 October 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

title

Targeting RET receptor tyrosine kinase activation in cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

Targeting RET Receptor Tyrosine Kinase Activation in Cancer (English)

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

author

John E Phay

series ordinal

1

object named as

John E. Phay

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930041

retrieved

29 July 2024

author name string

Manisha H. Shah

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930041

retrieved

29 July 2024

language of work or name

English

0 references

publication date

7 October 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

full work available at URL

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/24/5936

online access status

open access

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930041

retrieved

29 July 2024

https://aacrjournals.org/clincancerres/article-pdf/16/24/5936/1994026/5936.pdf

file format

Portable Document Format

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

published in

Clinical Cancer Research

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

volume

16

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

issue

24

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

page(s)

5936-5941

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

cites work

A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases

series ordinal

1

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

series ordinal

2

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

series ordinal

3

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.

series ordinal

4

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Functional receptor for GDNF encoded by the c-ret proto-oncogene

series ordinal

5

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

GDNF signalling through the Ret receptor tyrosine kinase

series ordinal

6

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

series ordinal

7

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

RET and neuroendocrine tumors

series ordinal

8

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease

series ordinal

10

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

RET proto-oncogene point mutations in sporadic neuroendocrine tumors

series ordinal

11

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.

series ordinal

12

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Medullary thyroid cancer: management guidelines of the American Thyroid Association

series ordinal

13

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

New therapeutic approaches to treat medullary thyroid carcinoma

series ordinal

14

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

series ordinal

16

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

series ordinal

17

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

BAY 43-9006 inhibition of oncogenic RET mutants

series ordinal

18

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

series ordinal

19

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

series ordinal

20

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

series ordinal

21

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

series ordinal

26

1 reference

stated in

Crossref

DOI

10.1158/1078-0432.CCR-09-0786

reference URL

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-0786

retrieved

29 July 2024

Identifiers

DOI

10.1158/1078-0432.CCR-09-0786

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

PubMed publication ID

20930041

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20930041

retrieved

23 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37798616&oldid=2218034098"